Aerie pharmaceuticals to announce third quarter 2019 financial results and host conference call on wednesday, november 6, 2019
Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its third quarter 2019 financial results will be released after the market closes on wednesday, november 6, 2019. following the release, the company will host a live conference call and webcast at 5:00 p.m. eastern time to discuss the company’s financial results and provide a general business update. the live webcast and a replay may be accessed by visiting the company’s website at http://investors.aeriepharma.com. please connect to the company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. alternatively, please call (888) 734-0328 (u.s.) or (678) 894-3054 (international) to listen to the live conference call. the conference id number for the live call is 3884357. please dial in approximately 10 minutes prior to the call. telephone replay will be available approximately two hours after the call. to access the replay, please call (855) 859-2056 (u.s.) or (404) 537-3406 (international). the conference id number for the replay is 3884357. the telephone replay will be available until november 14, 2019. about aerie pharmaceuticals, inc. aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. aerie's first product, rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the u.s. food and drug administration (fda) for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension, was launched in the united states in april 2018. in clinical trials of rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. more information about rhopressa®, including the product label, is available at www.rhopressa.com. aerie’s second product for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of rhopressa® and the widely-prescribed pga (prostaglandin analog) latanoprost, has been approved by the fda and is now available in the united states. in clinical trials of rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. more information about rocklatan®, including the product label, is available at www.rocklatan.com. aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. more information is available at www.aeriepharma.com.
AERI Ratings Summary
AERI Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission